As mentioned, DPP-4 inhibitors increase the concentration of endogenous GLP-1, leading to increased insulin secretion, decreased glucagon secretion, and decreased HbA1c in patients with T2DM
The second phase, "Trial Two" is seeking participants via their study's dedicated website, which also includes a fund-raising campaign
[2] For a patient managing conditions like leaky gut syndrome, irritable bowel disease, or NSAID-induced gastric injury, oral capsule formulations may therefore be both effective and logistically simpler than injection
Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial
UCLA Senate Core Grant to BHH and RPS
Managing these effects through dietary modifications and gradual dose titration is a standard part of GLP-1 therapy